A pharmaco-invasive strategy was associated with lower mortality compared to delayed (HR 1.3; 95% CI 1.0-1.5) and late pPCI (HR 1.4; 95% CI 1.1-1.7) in STEMI patients without timely access to pPCI.
Cohort (n=21,121)
Yes
Does a pharmaco-invasive strategy improve survival compared to delayed or late pPCI in STEMI patients who cannot receive timely pPCI?
In STEMI patients unable to receive timely pPCI, a pharmaco-invasive strategy is associated with better long-term survival compared to delayed or late pPCI, despite a higher risk of bleeding complications.
Effect estimate: HR 1.3 (delayed pPCI), HR 1.4 (late pPCI) (95% CI 1.0-1.5 (delayed pPCI), 1.1-1.7 (late pPCI))
AIMS: Primary percutaneous coronary intervention (pPCI) is the preferred reperfusion strategy in patients with ST-segment elevation myocardial infarction (STEMI) provided it can be performed within 120 min from diagnosis. However, it is unclear whether pPCI or a pharmaco-invasive (P-I) strategy is the best choice in patients who cannot receive timely pPCI. The aim of the present study was to compare outcomes after delayed and late pPCI vs. a P-I strategy in STEMI patients who did not receive timely pPCI. METHODS AND RESULTS: All patients with STEMI registered in the Norwegian Myocardial Infarction Registry (NORMI) between 2013 and 2019, with ≤12 h from symptom onset to first medical contact and available timelines were included in the study. The primary outcome was all-cause mortality, and follow-up was through 2019. A total of 21 121 (27% of 78 368) STEMI patients were registered in the NORMI. Among patients who met the inclusion criteria, 7238 (54%) patients underwent timely pPCI, 1537 (11%) delayed pPCI (121-180 min), 1012 (7%) late pPCI (>180 min), and 2338 (17%) patients were treated with a P-I strategy. After a median follow-up time of 2.5 years, mortality was higher in the delayed pPCI adjusted hazard ratio (HR) 1.3, 95% confidence interval (CI) 1.0-1.5 and in the late pPCI group (adjusted HR 1.4, 95% CI 1.1-1.7) compared to the P-I strategy group, but bleeding complications were more frequent after P-I strategy. CONCLUSIONS: In STEMI patients who did not receive timely percutaneous coronary intervention, a P-I strategy seemed to be associated with better long-term survival compared to delayed/late pPCI.
Jortveit et al. (Tue,) conducted a cohort in ST-segment elevation myocardial infarction (STEMI) (n=21,121). Delayed (121-180 min) or late (>180 min) primary percutaneous coronary intervention vs. Pharmaco-invasive (P-I) strategy was evaluated on All-cause mortality (HR 1.3 (delayed pPCI), HR 1.4 (late pPCI), 95% CI 1.0-1.5 (delayed pPCI), 1.1-1.7 (late pPCI)). A pharmaco-invasive strategy was associated with lower mortality compared to delayed (HR 1.3; 95% CI 1.0-1.5) and late pPCI (HR 1.4; 95% CI 1.1-1.7) in STEMI patients without timely access to pPCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: